Evidence map›Paper›PMID 30343942›Full record

ArticleAmerican journal of human genetics2018

Missense Mutations of the Pro65 Residue of PCGF2 Cause a Recognizable Syndrome Associated with Craniofacial, Neurological, Cardiovascular, and Skeletal Features.

Peter D Turnpenny, Michael J Wright, Melissa Sloman, Richard Caswell, Anthony J van Essen, Erica Gerkes, Rolph Pfundt, Susan M White, Nava Shaul-Lotan, Lori Carpenter and 16 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Polycomb-mediated 3D chromatin interactions in gene regulation.Current opinion in genetics & development · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Macrocephaly and Finger Changes: A Narrative Review.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 19 institutions in 8 countries.

Peter D TurnpennyPeninsula Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter EX1 2ED, UK. Electronic address: peter.turnpenny@nhs.net.
Michael J WrightNorthern Genetics Service, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle NE1 3BZ, UK.
Melissa SlomanDepartment of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, UK.
Richard CaswellInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter EX1 2LU, UK.
Anthony J van EssenDepartment of Genetics, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, the Netherlands.
Erica GerkesDepartment of Genetics, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, the Netherlands.
Rolph PfundtHuman Genetics, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, the Netherlands.
Susan M WhiteVictorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria 3052, Australia; Department of Paediatrics, University of Melbourne, Parkville, Victoria 3052, Australia.
Nava Shaul-LotanClinical Genetics, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem 91120, Israel.
Lori CarpenterSaint Francis Genetics, Tulsa, Oklahoma 74136, USA.
G Bradley SchaeferUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Alan FryerCheshire and Merseyside Clinical Genetic Service, Liverpool Women's NHS Foundation Trust, Liverpool L8 7SS, UK.
A Micheil InnesDepartment of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta T3B 6A8, Canada.
Kirsten P ForbesDepartment of Neuroradiology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
Wendy K ChungDepartments of Pediatrics and Medicine, Columbia University, New York, NY 10032, USA.
Heather McLaughlinGeneDx, Gaithersburg, Maryland 20877, USA.
Lindsay B HendersonGeneDx, Gaithersburg, Maryland 20877, USA.
Amy E RobertsCardiovascular Genetics, Department of Cardiology and Division of Genetics, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts 02115, USA.
Karen E HeathInstitute of Medical & Molecular Genetics (INGEMM) and Skeletal Dysplasia Multidisciplinary Unit (UMDE), Hospital Universitario la Paz, Universidad Autónoma de Madrid, IdiPAZ, 28046 Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCII), 28029 Madrid, Spain.
Beatriz Paumard-HernándezInstitute of Medical & Molecular Genetics (INGEMM) and Skeletal Dysplasia Multidisciplinary Unit (UMDE), Hospital Universitario la Paz, Universidad Autónoma de Madrid, IdiPAZ, 28046 Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCII), 28029 Madrid, Spain.
Blanca GenerCentro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCII), 28029 Madrid, Spain; Department of Genetics, Cruces University Hospital, Biocruces Health Research Institute, 48903 Barakaldo, Bizkaia, Spain.
DDD studyWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
Katherine A FawcettMRC Computational Genomics Analysis and Training Programme (CGAT), MRC Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.
Romana Gjergja-JuraškiMedical School of Osijek, Josip Juraj Strossmayer University, Neuropediatric Unit, Children's Hospital Srebrnjak, CRO-10000 Zagreb, Croatia.
Daniela T PilzWest of Scotland Genetic Services, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
Andrew E FryInstitute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4XW, UK; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. Electronic address: fryae@cardiff.ac.uk.
Hospital Universitario La Paz · ESQueen Elizabeth University Hospital · GBRoyal Devon & Exeter NHS Foundation Trust · GBUniversity Medical Center Groningen · NLBoston Children's Hospital · USChildren's Hospital Srebrnjak · HRColumbia University · USHadassah Medical Center · ILInstituto de Salud Carlos III · ESJohn Radcliffe Hospital · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRadboud University Nijmegen · NLSaint Francis Hospital · USThe University of Melbourne · AUUniversity Hospital of Wales · GBUniversity of Arkansas for Medical Sciences · USUniversity of Calgary · CAUniversity of Exeter · GBUniversity of Liverpool · GB

Funding

Medical Research Council MC_PC_15065Wellcome Trust
6 · The paper itself

Abstract

PCGF2 encodes the polycomb group ring finger 2 protein, a transcriptional repressor involved in cell proliferation, differentiation, and embryogenesis. PCGF2 is a component of the polycomb repressive complex 1 (PRC1), a multiprotein complex which controls gene silencing through histone modification and chromatin remodelling. We report the phenotypic characterization of 13 patients (11 unrelated individuals and a pair of monozygotic twins) with missense mutations in PCGF2. All the mutations affected the same highly conserved proline in PCGF2 and were de novo, excepting maternal mosaicism in one. The patients demonstrated a recognizable facial gestalt, intellectual disability, feeding problems, impaired growth, and a range of brain, cardiovascular, and skeletal abnormalities. Computer structural modeling suggests the substitutions alter an N-terminal loop of PCGF2 critical for histone biding. Mutant PCGF2 may have dominant-negative effects, sequestering PRC1 components into complexes that lack the ability to interact efficiently with histones. These findings demonstrate the important role of PCGF2 in human development and confirm that heterozygous substitutions of the Pro65 residue of PCGF2 cause a recognizable syndrome characterized by distinctive craniofacial, neurological, cardiovascular, and skeletal features.

Indexed as

dysmorphismintellectual disabilityMEL18PCGF2Polycomb Group Ring Finger 2polymicrogyria

Identifiers

PMID30343942
PMCPMC6218713
OpenAlexW2897624000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.